We serve Chemical Name:5-(3-Bromophenyl)-1-methyl-1H-imidazole CAS:1218910-50-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-(3-Bromophenyl)-1-methyl-1H-imidazole
CAS.NO:1218910-50-9
Synonyms:5-(3-Bromophenyl)-1-methyl-1H-imidazole
Molecular Formula:C10H9BrN2
Molecular Weight:237.09600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:17.82000
Exact Mass:235.99500
LogP:2.84960
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-(3-Bromophenyl)-1-methyl-1H-imidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(3-Bromophenyl)-1-methyl-1H-imidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(3-Bromophenyl)-1-methyl-1H-imidazole Use and application,5-(3-Bromophenyl)-1-methyl-1H-imidazole technical grade,usp/ep/jp grade.
Related News: This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 5-(3-Bromophenyl)-1-methyl-1H-imidazole manufacturer This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 5-(3-Bromophenyl)-1-methyl-1H-imidazole supplier Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 5-(3-Bromophenyl)-1-methyl-1H-imidazole vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 5-(3-Bromophenyl)-1-methyl-1H-imidazole factory Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer.
